title: Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment.
abstract: An untreated 66-year-old woman with chronic myelogenous leukaemia (CML) in the chronic phase was initially given imatinib mesylate, rapidly achieving a good cytogenetic response with treatment. However, acute promyelocytic leukaemia complicated by a disseminated intravascular coagulation occurred 9 months after beginning imatinib treatment. Promyelocytic crisis of CML was diagnosed by demonstration of both BCR/ABL and PML/RAR alpha chimeric genes in leukaemic cells by karyotypic and fluorescence in situ hybridization analysis. Clonal evolution with addition of the PML/RAR alpha translocation may have arisen in the early chronic phase of CML, with expansion of this clone during imatinib treatment. Promyelocytic crisis of CML is rare; furthermore, we know of no previous report of promyelocytic crisis occurring during treatment with imatinib.
authors.affiliation: Division of Haematology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
authors.forename: Eijiro
authors.initials: E
authors.lastname: Oku
authors.forename: Rie
authors.initials: R
authors.lastname: Imamura
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Nagata
authors.forename: Yuka
authors.initials: Y
authors.lastname: Takata
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Seki
authors.forename: Korenori
authors.initials: K
authors.lastname: Otsubo
authors.forename: Michitoshi
authors.initials: M
authors.lastname: Hashiguchi
authors.forename: Koichi
authors.initials: K
authors.lastname: Osaki
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Yakushiji
authors.forename: Kohji
authors.initials: K
authors.lastname: Yoshimoto
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ogata
authors.forename: Michio
authors.initials: M
authors.lastname: Sata
authors.forename: Takashi
authors.initials: T
authors.lastname: Okamura
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents; D001549:Benzamides; D005434:Flow Cytometry; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate